Enhertu
BostonGene, Hokkaido University to Study Biomarkers of Response in HER2-Positive Breast Cancer
The collaborators aim to use BostonGene's algorithms and genomics tools to identify HER2-positive breast cancer patients likely to respond to certain therapies.
Guardant Health Receives Guardant360 CDx Regulatory Approval in Japan for HER2 Lung Cancer Treatment
Patients who test positive for a HER2 mutation and have seen their disease progress after chemotherapy can now be treated with Daiichi Sankyo's Enhertu.